ICF biotech equity investment
Executive Summary
Washington, D.C. consulting firm has invested $3 mil. in New Haven, Connecticut-based Bios, a year-old biotech company developing DNA blots and DNA research equipment. The agreement, which involves a $1.5 mil. up-front payment with the balance in milestone payments over the next two to three years, is ICF's first direct investment in health care-related R&D. ICF, a privately held consulting firm, recently merged with Lewin Associates, another D.C. consulting firm, which specializes in health care. ICF had revenues of $68 mil. in 1986.
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: